METROPOLIS

NextGen liqui CORE
52 gene panel

Patient Selection	Technology	Specimen	Test Code	TAT
For patients with advancedsolid tumors	Next Generation Sequencing	Blood	N8279	20 days

cfTNA (Cell-free total nucleic acid- DNA & RNA) based assay that identifies clinically relevant genomic alterations within the 52 genes

Validated on clinical research samples and detects somatic variants as low as 0.1% frequencies

- Sensitivity and specificity : >99%
- 100% concordance with ddPCR samples and Horizon controls results for SNVs and Short Indels

Alteration Type	Genes Covered
CoveredHotspot genes (SNVs) and Short Indels	AKT1, ALK, AR, ARAF, BRAF, CHEK2, CTNNB1, DDR2,EGFR, ERBB2, ERBB3, ESR1, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, GNA11, GNAQ, GNAS, HRAS, IDH1, IDH2, KIT, KRAS, MAP2K1, MAP2K2, MET, MTOR, NRAS, NTRK1, NTRK3, PDGFRA, PIK3CA, RAF1, RET, ROS1, SF3B1, SMAD4, SMO
Gene fusions	ALK, BRAF, ERG, ETV1, FGFR1, FGFR2, FGFR3, MET, NTRK1, NTRK3, RET, ROS1
ROS1Copy Number Variations (CNVs)	CCND1, CCND2, CCND3, CDK4, CDK6, EGFR, ERBB2, FGFR1, FGFR2, FGFR3, MET, MYC
Tumor suppressor genes	APC, FBXW7, PTEN, TP53
Extra	MET exon 14 skipping

METROPOLIS

NextGen liqui CORE 52 gene Panel

Your Test Results

Patient Name:

Age/Sex:

Patient Location:

Hospital Name:

Physician Name:

Date & Time of Accessioning:

Date & Time of Reporting:

Test Information

NextGen liquiCORE 52 gene panel is a Next Generation Sequencing (NGS) based assay that identifies clinically relevant genomic alterations (SNVs, short indels, fusions and CNVs) within the 52 genes that are most frequently al-tered in majority of cancers, including, lung, breast, colorectal, melanoma, prostate, ovarian, gastric, bladder, brain, CNS, cervical, endometrial, esophageal, head & neck, kidney, liver, pancreatic, sarcoma, thyroid and en-dometrial (Detailed information has been provided in additional information section).

Specimen Information

Clinical History

NSCLC.

Results

A clinically relevant variant was detected in this patient

S.No.	Genomic Alterations	Associated FDA Approved Therapies (in this cancer type)	Associated FDA Approved Therapies (in other cancer type; Off Label Suggestions)	Clinical trials
1	EGFR, exon 19 deletion	Afatinib, Dacomitinib, Erlotinib, Gefitinib and Osimertinib	None	4 (Please refer to page no. 4 for more details)